Plasma levels of tissue inhibitor of matrix metalloproteinase-1 correlate with diagnosis and prognosis of glioma patients

Chinese Medical Journal

Volumn 126, Issue 22, 2013, Pages 4295-4300

  Lin, Yi ^a   Wang, Jiang Fei ^b   Gao, Guang Zu ^c   Zhang, Guo Zhen ^b   Wang, Fei Long ^a   Wang, Yun Jie ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biomarker; Glioma; Metalloproteinase 9; Plasma; Tissue inhibitor of metalloproteinase 1

Indexed keywords

BIOLOGICAL MARKER; GELATINASE B; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOLOGY; PROTEIN EXPRESSION; REGRESSION ANALYSIS; TUMOR RECURRENCE;

ADULT; CASE-CONTROL STUDIES; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 84887579807     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20131765     Document Type: Article

References (24)

1. James CD, Cavenee WK. Molecular biology of central nervous system tumors. In: Devita VT, ed. Cancer: principles and practice of oncology, 9th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2011: 1692-1699.
2. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 2010; 12: 116-121.
3. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 2008; 18: 360-369.
4. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010; 75: 1560-1566.
5. Rees JH. Diagnosis and treatment in neuro-oncology: an oncological perspective. Br J Radiol 2011; 84 Spec No: S82-S89.
6. Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, et al. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol 2011; 13: 1244-1251.
7. Liu BL, Cheng JX, Zhang W, Zhang X, Wang R, Lin H, et al. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro Oncol 2010; 12: 540-548.
8. Iwadate Y, Hayama M, Adachi A, Matsutani T, Nagai Y, Hiwasa T, et al. High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. Anticancer Res 2008; 28: 415-418.
9. Todaro L, Christiansen S, Varela M, Campodonico P, Pallotta MG, Lastiri J, et al. Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol 2007; 83: 135-144.
10. Fukuda ME, Iwadate Y, Machida T, Hiwasa T, Nimura Y, Nagai Y, et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res 2005; 65: 5190-5194.
11. Lin Y, Jiang T, Zhou K, Xu L, Chen B, Li G, et al. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol 2009; 11: 468-476.
12. Elstner A, Stockhammer F, Nguyen-Dobinsky TN, Nguyen QL, Pilgermann I, Gill A, et al. Identification of diagnostic serum protein profiles of glioblastoma patients. J Neurooncol 2011; 102: 71-80.
13. Lin Y, Jin Q, Zhang GZ, Wang YJ, Jiang T, Wu AH, et al. Increase of plasma IgE during treatment correlates with better outcome of patients with glioblastoma. Chin Med J 2011; 124: 3042-3048.
14. Lin Y, Zhang G, Zhang J, Gao G, Li M, Chen Y, et al. A panel of four cytokines predicts the prognosis of patients with malignant gliomas. J Neurooncol 2013; 114: 199-208.
15. Matsukado Y, Maccarty CS, Kernohan JW. The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. J Neurosurg 1961; 18: 636-644.
16. Bell E Jr, Karnosh LJ. Cerebral hemispherectomy; report of a case 10 years after operation. J Neurosurg 1949; 6: 285-293.
17. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008; 40: 1362-1378.
18. Sato H, Takino T. Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion. Cancer Sci 2010; 101: 843-847.
19. Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 1995; 83: 298-307.
20. Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 1999; 79: 1828-1835.
21. Wang M, Wang T, Liu S, Yoshida D, Teramoto A. The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol 2003; 20: 65-72.
22. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 2006; 12: 5698-5704.
23. Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, et al. Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. J Neurooncol 2011; 105: 607-612.
24. Sounni NE, Janssen M, Foidart JM, Noel A. Membrane type- 1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol 2003; 22: 55-61.